$65.88
-0.82-1.23%
Last update: Aug 24, 10:59 AM
BioMarin Pharmaceutical Inc
BMRNNASDAQ
M&A: Alesta Therapeutics announced it will be acquired by BioMarin Pharmaceutical (BMRN) on Tuesday, August 18, 2026 for $275M
BioMarin Pharmaceutical Earnings & Forecasts
BioMarin Pharmaceutical (BMRN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
BioMarin Pharmaceutical Guidance
BioMarin Pharmaceutical (BMRN) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided earnings per share in the range of $4.9 - $5.1, compared to a consensus EPS estimate of $4.8. BioMarin Pharmaceutical also guided revenue in the range of $3.88B - $3.92B for the period.
Compared to prior guidance, BioMarin Pharmaceutical raised its EPS outlook from a previous range of $4.85 - $5.05. On the revenue side, the company maintained its revenue forecast from a prior range of $3.83B - $3.92B.
BioMarin Pharmaceutical has issued 20 guidance updates between October 26, 2022 and August 6, 2026. During this period, the company raised its outlook 11 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.92 | $0.89 | $0.36 | $0.51 |
| Actual | $1.20 | $0.76 | $0.46 | $0.12 |
| Surprise | +30.4% | -14.6% | +27.8% | -76.5% |
| Revenue | ||||
| Estimate | $931.3M | $754.6M | $832.9M | $781.9M |
| Actual | $990.0M | $766.2M | $875.0M | $776.1M |
| Surprise | +6.30% | +1.54% | +5.06% | -0.74% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $1.34 | $1.68 | $1.31 | $1.44 |
| Revenue | ||||
| Consensus | $1.03B | $1.12B | — | — |
